Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Phase 2
Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin is one of 48 therapeutic programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
56 competitors in Carcinoma, Non-Small-Cell Lung
#DrugCompanyPhaseTrials
1Rybrevant
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Lazcluze
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Taxol
TevaPhase 3
Paraplatin
AAvyxa
Phase 3
Tagrisso
AstraZenecaPhase 3
Alimta
GGynecologic Oncology Group
Phase 3
Gemzar
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]